vations about processes beget inferences that occasionally beget predictions that occasionally beget recommendations.
In this issue, we see several attempts to understand or respond to the processes that underlie dysfunction. Capuzzi and Freeman implicate CRP in the atherogenic process, characterize its potential in predicting cardiovascular events, and review two large well-conducted studies that suggest CRP's association with the development of diabetes. These observations contribute to our understanding of the dysfunction associated with diabetes. Yet, one ought to be circumspect in transitioning from processes underlying disease to recommendations. This is especially relevant in diabetes, which is treated as the equivalent of having had a coronary event and thereby already necessitates intensive attention to known coronary risk factors. In addition, recommendations for monitoring are rarely associated with the same rigor as recommendations for treatment. Although the consequences of monitoring are unlikely to result in fulminant MD (p. 25), after reviewing the burden of diabetes, gives a tree-level view of the mechanism underlying the four categories of diabetes as part of "Diabetes: A Foundation," another new department aimed at equipping physicians-in-training with core knowledge of diabetes. It is notable how simple our current diabetes classification system remains, despite significant advances in our understanding of the heterogeneous condition we call diabetes. Finally, David M. Capuzzi, MD, PhD, and Jeffrey S. Freeman, DO (p. 16), give leaflevel attention to a particular peptide that is sometimes elevated in diabetes: C-reactive protein (CRP). CRP is indiscriminately elevated in a variety of inflammatory conditions, and Capuzzi and Freeman make the case that inflammation is a key attribute of diabetes and that CRP has an important role in at least predicting future macrovascular events. An argument follows in support of recommendations for measuring CRP in certain populations.
It has been said that there are three common denominators of disease pathogenesis: inflammation, oxidation, and coagulation. Although such characterizations are simple if not simplistic, it is remarkable how many conditions appear to involve disturbances of these three "denominators" at some point along the continuum that characterizes their pathogenesis. Type 2 diabetes, unlike type 1, is perceived by some physicians to not involve these mecha- The contribution of inflammation will continue to be unraveled in both atherogenic processes and diabetes. Additional compounds, perhaps somewhat less promiscuous than CRP, will be identified, and the role of known peptides will be further clarified. Whether CRP is the pawn or the queen remains to be seen. 
